Related Experiment Video
Updated: Feb 20, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Antihyperlipidemic effect of Pistacia khinjuk
Faiza Kamal1, Muhammad Shahzad2, Tanveer Ahmad3
1Department of Home and Health Sciences, Allama Iqbal Open University Islamabad, Pakistan.
Background:
Hyperlipidemia is a metabolic disorder that is caused by high levels of triglycerides and cholesterol in blood. Using of plants for the treatment of various ailments is a traditional practice in developing countries. The main objective of the study is to analyse the nutritional composition of Pistacia khinjuk and to assess its anti-hyperlipidemic activity.
Materials And Methods:
In the present study, the ethanolic extract of Pistacia khinjuk leaves was evaluated for antihyperlipidemic activity. 40 adult albino rats were divided into five groups. Hyperlipidemia was induced using high fat diet for 60days. Pistacia khinjuk extract of 150mg/kg body weight and 300mg/kg of body weight was administered to the rats for 28days. Proximate analysis of Pistacia khinjuk was also performed.
Results:
Proximate analysis of Pistacia khinjuk leaves showed 6.8% ash content, 12.8% crude fiber and only 6.85% fat content. Findings of present study revealed that both doses of Pistacia khinjuk extract improved the serum lipid profile in albino rats by reducing total lipids, total cholesterol, triglycerides and low density lipoprotein, and increasing high density lipoprotein levels in Pistacia khinjuk treated groups. Body weight findings showed significant increase in body weight of all groups from zero day to 60th day. But before sacrifice, there was a decrease in hyperlipidemic and high dose Pistacia khinjuk while increase in control and low dose Pistacia khinjuk group respectively.
Conclusion:
From the results of the present study, it is concluded that Pistacia khinjuk extract has curative effect against hyperlipidemia.
More Related Videos
09:15Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Atherosclerosis III: Management
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Dipeptidyl Peptidase 4 Inhibitors